nodes	percent_of_prediction	percent_of_DWPC	metapath
Alvimopan—Hypokalaemia—Temsirolimus—kidney cancer	0.0224	0.0226	CcSEcCtD
Alvimopan—Urinary retention—Everolimus—kidney cancer	0.0174	0.0176	CcSEcCtD
Alvimopan—Urinary tract disorder—Temsirolimus—kidney cancer	0.0168	0.017	CcSEcCtD
Alvimopan—Connective tissue disorder—Temsirolimus—kidney cancer	0.0168	0.0169	CcSEcCtD
Alvimopan—Urethral disorder—Temsirolimus—kidney cancer	0.0167	0.0168	CcSEcCtD
Alvimopan—Hypokalaemia—Everolimus—kidney cancer	0.0167	0.0168	CcSEcCtD
Alvimopan—Hypokalaemia—Erlotinib—kidney cancer	0.0161	0.0162	CcSEcCtD
Alvimopan—Urinary tract disorder—Pazopanib—kidney cancer	0.0159	0.016	CcSEcCtD
Alvimopan—Connective tissue disorder—Pazopanib—kidney cancer	0.0158	0.0159	CcSEcCtD
Alvimopan—Urethral disorder—Pazopanib—kidney cancer	0.0158	0.0159	CcSEcCtD
Alvimopan—Malnutrition—Temsirolimus—kidney cancer	0.0148	0.015	CcSEcCtD
Alvimopan—Hypokalaemia—Sorafenib—kidney cancer	0.0145	0.0146	CcSEcCtD
Alvimopan—Back pain—Temsirolimus—kidney cancer	0.0144	0.0145	CcSEcCtD
Alvimopan—Malnutrition—Pazopanib—kidney cancer	0.014	0.0141	CcSEcCtD
Alvimopan—Hypokalaemia—Sunitinib—kidney cancer	0.0139	0.014	CcSEcCtD
Alvimopan—Flatulence—Pazopanib—kidney cancer	0.0138	0.0139	CcSEcCtD
Alvimopan—Anaemia—Temsirolimus—kidney cancer	0.0137	0.0138	CcSEcCtD
Alvimopan—Anaemia—Pazopanib—kidney cancer	0.0129	0.013	CcSEcCtD
Alvimopan—Urinary tract disorder—Everolimus—kidney cancer	0.0125	0.0126	CcSEcCtD
Alvimopan—Connective tissue disorder—Everolimus—kidney cancer	0.0125	0.0126	CcSEcCtD
Alvimopan—Urethral disorder—Everolimus—kidney cancer	0.0124	0.0125	CcSEcCtD
Alvimopan—Urinary retention—Vincristine—kidney cancer	0.0123	0.0124	CcSEcCtD
Alvimopan—Urinary tract disorder—Erlotinib—kidney cancer	0.0121	0.0122	CcSEcCtD
Alvimopan—Connective tissue disorder—Erlotinib—kidney cancer	0.012	0.0121	CcSEcCtD
Alvimopan—Urethral disorder—Erlotinib—kidney cancer	0.012	0.0121	CcSEcCtD
Alvimopan—Hypokalaemia—Gemcitabine—kidney cancer	0.0112	0.0113	CcSEcCtD
Alvimopan—Malnutrition—Everolimus—kidney cancer	0.011	0.0111	CcSEcCtD
Alvimopan—Flatulence—Everolimus—kidney cancer	0.0109	0.011	CcSEcCtD
Alvimopan—Urinary tract disorder—Sorafenib—kidney cancer	0.0109	0.011	CcSEcCtD
Alvimopan—Connective tissue disorder—Sorafenib—kidney cancer	0.0108	0.0109	CcSEcCtD
Alvimopan—Urethral disorder—Sorafenib—kidney cancer	0.0108	0.0109	CcSEcCtD
Alvimopan—Back pain—Everolimus—kidney cancer	0.0107	0.0108	CcSEcCtD
Alvimopan—Malnutrition—Erlotinib—kidney cancer	0.0107	0.0107	CcSEcCtD
Alvimopan—Flatulence—Erlotinib—kidney cancer	0.0105	0.0106	CcSEcCtD
Alvimopan—Urinary tract disorder—Sunitinib—kidney cancer	0.0105	0.0105	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Temsirolimus—kidney cancer	0.0105	0.0105	CcSEcCtD
Alvimopan—Connective tissue disorder—Sunitinib—kidney cancer	0.0104	0.0105	CcSEcCtD
Alvimopan—Urethral disorder—Sunitinib—kidney cancer	0.0104	0.0105	CcSEcCtD
Alvimopan—Constipation—Temsirolimus—kidney cancer	0.0104	0.0104	CcSEcCtD
Alvimopan—Back pain—Erlotinib—kidney cancer	0.0103	0.0104	CcSEcCtD
Alvimopan—Anaemia—Vinblastine—kidney cancer	0.0102	0.0103	CcSEcCtD
Alvimopan—Anaemia—Everolimus—kidney cancer	0.0102	0.0103	CcSEcCtD
Alvimopan—Dyspepsia—Pazopanib—kidney cancer	0.0101	0.0101	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Pazopanib—kidney cancer	0.00986	0.00993	CcSEcCtD
Alvimopan—Malnutrition—Sorafenib—kidney cancer	0.00959	0.00966	CcSEcCtD
Alvimopan—Hypokalaemia—Paclitaxel—kidney cancer	0.00937	0.00943	CcSEcCtD
Alvimopan—Malnutrition—Sunitinib—kidney cancer	0.00923	0.00929	CcSEcCtD
Alvimopan—Flatulence—Sunitinib—kidney cancer	0.00909	0.00916	CcSEcCtD
Alvimopan—Back pain—Sunitinib—kidney cancer	0.00892	0.00899	CcSEcCtD
Alvimopan—Anaemia—Sorafenib—kidney cancer	0.00886	0.00892	CcSEcCtD
Alvimopan—Urinary tract disorder—Vincristine—kidney cancer	0.00885	0.00892	CcSEcCtD
Alvimopan—Connective tissue disorder—Vincristine—kidney cancer	0.00881	0.00887	CcSEcCtD
Alvimopan—Urethral disorder—Vincristine—kidney cancer	0.00879	0.00885	CcSEcCtD
Alvimopan—Anaemia—Sunitinib—kidney cancer	0.00853	0.00859	CcSEcCtD
Alvimopan—Urinary tract disorder—Gemcitabine—kidney cancer	0.0084	0.00846	CcSEcCtD
Alvimopan—Connective tissue disorder—Gemcitabine—kidney cancer	0.00836	0.00842	CcSEcCtD
Alvimopan—Urethral disorder—Gemcitabine—kidney cancer	0.00834	0.0084	CcSEcCtD
Alvimopan—Anaemia—Dactinomycin—kidney cancer	0.00807	0.00813	CcSEcCtD
Alvimopan—Urinary retention—Capecitabine—kidney cancer	0.00803	0.00809	CcSEcCtD
Alvimopan—Dyspepsia—Everolimus—kidney cancer	0.00794	0.00799	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Everolimus—kidney cancer	0.00778	0.00784	CcSEcCtD
Alvimopan—Constipation—Vinblastine—kidney cancer	0.00774	0.00779	CcSEcCtD
Alvimopan—Constipation—Everolimus—kidney cancer	0.00771	0.00776	CcSEcCtD
Alvimopan—Hypokalaemia—Capecitabine—kidney cancer	0.00769	0.00774	CcSEcCtD
Alvimopan—Dyspepsia—Erlotinib—kidney cancer	0.00766	0.00771	CcSEcCtD
Alvimopan—Back pain—Vincristine—kidney cancer	0.00755	0.0076	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Erlotinib—kidney cancer	0.00751	0.00756	CcSEcCtD
Alvimopan—Constipation—Erlotinib—kidney cancer	0.00744	0.00749	CcSEcCtD
Alvimopan—Anaemia—Vincristine—kidney cancer	0.00721	0.00726	CcSEcCtD
Alvimopan—Back pain—Gemcitabine—kidney cancer	0.00716	0.00721	CcSEcCtD
Alvimopan—Urinary tract disorder—Paclitaxel—kidney cancer	0.00703	0.00708	CcSEcCtD
Alvimopan—Connective tissue disorder—Paclitaxel—kidney cancer	0.007	0.00705	CcSEcCtD
Alvimopan—Urethral disorder—Paclitaxel—kidney cancer	0.00698	0.00703	CcSEcCtD
Alvimopan—Dyspepsia—Sorafenib—kidney cancer	0.00689	0.00694	CcSEcCtD
Alvimopan—Anaemia—Gemcitabine—kidney cancer	0.00684	0.00689	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Sorafenib—kidney cancer	0.00676	0.0068	CcSEcCtD
Alvimopan—Constipation—Sorafenib—kidney cancer	0.00669	0.00674	CcSEcCtD
Alvimopan—Dyspepsia—Sunitinib—kidney cancer	0.00663	0.00668	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Sunitinib—kidney cancer	0.0065	0.00655	CcSEcCtD
Alvimopan—Constipation—Sunitinib—kidney cancer	0.00644	0.00648	CcSEcCtD
Alvimopan—Malnutrition—Paclitaxel—kidney cancer	0.0062	0.00624	CcSEcCtD
Alvimopan—Flatulence—Paclitaxel—kidney cancer	0.00611	0.00615	CcSEcCtD
Alvimopan—Back pain—Paclitaxel—kidney cancer	0.006	0.00604	CcSEcCtD
Alvimopan—Urinary tract disorder—Capecitabine—kidney cancer	0.00577	0.00581	CcSEcCtD
Alvimopan—Connective tissue disorder—Capecitabine—kidney cancer	0.00574	0.00578	CcSEcCtD
Alvimopan—Anaemia—Paclitaxel—kidney cancer	0.00573	0.00577	CcSEcCtD
Alvimopan—Urethral disorder—Capecitabine—kidney cancer	0.00573	0.00577	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Vincristine—kidney cancer	0.0055	0.00554	CcSEcCtD
Alvimopan—Constipation—Vincristine—kidney cancer	0.00545	0.00548	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.00522	0.00525	CcSEcCtD
Alvimopan—Constipation—Gemcitabine—kidney cancer	0.00517	0.0052	CcSEcCtD
Alvimopan—Malnutrition—Capecitabine—kidney cancer	0.00509	0.00512	CcSEcCtD
Alvimopan—Flatulence—Capecitabine—kidney cancer	0.00501	0.00505	CcSEcCtD
Alvimopan—Hypokalaemia—Doxorubicin—kidney cancer	0.00495	0.00499	CcSEcCtD
Alvimopan—Back pain—Capecitabine—kidney cancer	0.00492	0.00495	CcSEcCtD
Alvimopan—Anaemia—Capecitabine—kidney cancer	0.0047	0.00473	CcSEcCtD
Alvimopan—Dyspepsia—Paclitaxel—kidney cancer	0.00445	0.00448	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.00437	0.0044	CcSEcCtD
Alvimopan—Constipation—Paclitaxel—kidney cancer	0.00433	0.00436	CcSEcCtD
Alvimopan—Urinary tract disorder—Doxorubicin—kidney cancer	0.00372	0.00375	CcSEcCtD
Alvimopan—Connective tissue disorder—Doxorubicin—kidney cancer	0.0037	0.00373	CcSEcCtD
Alvimopan—Urethral disorder—Doxorubicin—kidney cancer	0.00369	0.00372	CcSEcCtD
Alvimopan—Dyspepsia—Capecitabine—kidney cancer	0.00365	0.00368	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Capecitabine—kidney cancer	0.00358	0.00361	CcSEcCtD
Alvimopan—Constipation—Capecitabine—kidney cancer	0.00355	0.00358	CcSEcCtD
Alvimopan—Malnutrition—Doxorubicin—kidney cancer	0.00328	0.0033	CcSEcCtD
Alvimopan—Flatulence—Doxorubicin—kidney cancer	0.00323	0.00325	CcSEcCtD
Alvimopan—Back pain—Doxorubicin—kidney cancer	0.00317	0.00319	CcSEcCtD
Alvimopan—Anaemia—Doxorubicin—kidney cancer	0.00303	0.00305	CcSEcCtD
Alvimopan—Indinavir—ABCB1—kidney cancer	0.00276	0.392	CrCbGaD
Alvimopan—Ketoprofen—PTGS1—kidney cancer	0.00273	0.387	CrCbGaD
Alvimopan—Dyspepsia—Doxorubicin—kidney cancer	0.00236	0.00237	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.00231	0.00233	CcSEcCtD
Alvimopan—Constipation—Doxorubicin—kidney cancer	0.00229	0.0023	CcSEcCtD
Alvimopan—Ketoprofen—PTGS2—kidney cancer	0.00156	0.221	CrCbGaD
